

Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting
600 East Broad Street –1st Floor Conference Rooms
Richmond, Virginia 23219
Thursday, October 15, 2026 - 1:00 p.m.

Welcome

**JoeMichael Fusco, PharmD, Pharmacy
Operations Manager**

Comments from DMAS' Director

Steve Ford, Medicaid Director

Call to Order

Greg Barabell MD, CMO, Chair

Drug Utilization Review (DUR) Board Update

Rachel Cain, PharmD

Approval of Minutes from July 16, 2026

P&T Committee Members

PDL Management

P&T Committee Members

Old business

PDL Quarter 4 – New Drug Review (Therapeutic Class)

PDL Quarter 4– Annual Class Review -

Antibiotics/Anti-Infectives

- Vaginal Antibiotics

Blood Modifiers

- Bile Salts
- Hemophilia Treatment (Closed Class)
- Phosphate Binders
- Sickle Cell (Closed Class)

Central Nervous System

- Anticonvulsants (Closed Class)
- Antipsychotics (includes oral and long acting injectables) (Closed Class)
- Antidepressants, SSRI
- Antidepressants, Other
- Movement Disorders (Closed Class)
- Sedatives / Hypnotics

Dermatitis

- Immunomodulators, Atopic Dermatitis (Closed Class)
- Steroids, Topical

Genitourinary

- Urinary Antispasmodics (Bladder Relaxants)
- Alpha-Blockers and Androgen Hormone Inhibitors for Benign Prostatic Hypertrophy (BPH)

Ophthalmic

- Allergic Conjunctivitis (includes Ophthalmic Antihistamines & Mast Cell Stabilizers)
- Antibiotics
- Antibiotic/Steroid Combinations
- Anti-Inflammatory Agents (includes Ophthalmic NSAIDS & Corticosteroids)
- Anti-Inflammatory Immunomodulator (Closed Class)
- Glaucoma Agents

Confidential Meeting (Pricing Information Discussion)

P&T Committee Members & DMAS Staff

PDL Recommendations and Vote

P&T Committee Members

Criteria Discussion of Quarter 4 New Drugs*

P&T Committee Members

Criteria Discussion of PDL Quarter 4 Drug Classes*

P&T Committee Members

Next Meeting - tentatively scheduled for January 21st 2027.

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral Presentations: The P&T Committee in conjunction with the Department will allocate time slots for interested parties to present scientific and clinical information on PDL off cycle drugs in classes in which are scheduled for review at the September meeting and new PDL Quarter 4 drugs listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Quarter 4 Annual Reviews – October 2025 to present
- **New** Drugs in off cycle Drug Classes – October 2024 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. The Chairperson will approve presentation requests based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must **submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter.** Please send requested information to pdlinput@dmass.virginia.gov and david.damico@primetherapeutics.com by 5 p.m. EST on Friday September 4th, 2026.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmass.virginia.gov by 5 p.m. EST on Friday September 4th, 2026.

DRAFT